Hepatocellular carcinoma (HCC) may recur after liver transplantation (LT), mainly in patients with multinodular and large tumors. However, factors predictive of outcome after LT in patients with small tumors remain ill defined. We investigated which factors were related to mortality or tumor recurrence among 47 liver transplant recipients with liver cirrhosis and HCC and compared them with 107 patients with liver cirrhosis without tumor who underwent LT in the same period. Patients with HCC were older (P < .001), more frequently had cirrhosis of a viral origin (P < .001), and had lower Child-Pugh scores (P < T he role of liver transplantation (LT) in the treatment of hepatocellular carcinoma (HCC) has evolved. In the early ages, LT was indicated in all cases of unresectable HCC without known extrahepatic spread. 1,2 Long-term survival was poor among patients with advanced disease because of a high incidence of tumor recurrence. 3 In the 1990s, several series showed that early HCC seldom recurred after LT and survival was similar in patients with cirrhosis with or without HCC. 2,4-6 Some prefer LT over resection in these patients. 2, [6] [7] [8] Several studies investigated which factors predispose to HCC recurrence after LT. Several investigators studied which factors are related to post-LT outcome. 2, 5, [8] [9] [10] [11] Llovet et al 5 did not find any factor predictive of post-LT outcome. In other series, poor differentiation, vascular invasion, greater number of tumor nodules, and greater tumor size were related to lower survival or disease-free survival rates, 2,8,9,11 but most series were based on unselected groups of patients and included a considerable proportion of patients with large nodules.
T he role of liver transplantation (LT) in the treatment of hepatocellular carcinoma (HCC) has evolved. In the early ages, LT was indicated in all cases of unresectable HCC without known extrahepatic spread. 1, 2 Long-term survival was poor among patients with advanced disease because of a high incidence of tumor recurrence. 3 In the 1990s, several series showed that early HCC seldom recurred after LT and survival was similar in patients with cirrhosis with or without HCC. 2, [4] [5] [6] Some prefer LT over resection in these patients. 2, [6] [7] [8] Several studies investigated which factors predispose to HCC recurrence after LT. Several investigators studied which factors are related to post-LT outcome. 2, 5, [8] [9] [10] [11] Llovet et al 5 did not find any factor predictive of post-LT outcome. In other series, poor differentiation, vascular invasion, greater number of tumor nodules, and greater tumor size were related to lower survival or disease-free survival rates, 2, 8, 9, 11 but most series were based on unselected groups of patients and included a considerable proportion of patients with large nodules.
The present study investigates factors associated with mortality and tumor recurrence among 47 patients with HCC who underwent LT according to well-defined selection criteria in a single center.
Patients and Methods
Between 1991 and June 2000 in our center, 160 adult patients with liver cirrhosis underwent a first LT. Forty-seven of these patients also had HCC diagnosed before LT, 6 patients had incidental HCC, and 107 patients had liver cirrhosis without HCC. Patients with incidental HCC were excluded from this retrospective study.
Patients with HCC were selected for LT if they had a single nodule not exceeding 60 mm in diameter or 2 or 3 tumors, none exceeding 50 mm in diameter, assessed by computed tomographic (CT) scan. Patients in whom vascular invasion or extrahepatic spread was evident preoperatively were excluded. LT was considered the treatment of choice for all patients with HCC if they fulfilled these criteria and did not have a contraindication for LT. Patients with HCC did not have a priority for LT compared to other patients with cirrhosis. During this period, only 2 patients were excluded from the LT waiting list 6 and 7 months after their listing because of progressing HCC.
As well as ultrasonography and CT scan, hepatic angiography was generally performed before LT. When HCC had been detected or suspected and it was technically feasible, hepatic angiography was followed by selective transarterial chemoembolization and lipiodol injection into both hepatic lobes. A postlipiodol CT scan was repeated 2 to 3 weeks later if the patient had not undergone LT by that time. If hepatic angiography had been performed before referral for LT, transarterial chemoembolization was performed only if the expected waiting period before LT was longer than 3 months. Preoperative staging of HCC included CT scan in all 47 cases, ultrasound in 45 cases, hepatic angiography in 43 cases, and postlipiodol CT scan in 37 cases. Extrahepatic spread was ruled out by bone scintigraphy, thoracic and abdominal CT scan, and brain magnetic resonance imaging.
Two patients had an HCC resected 1 and 8 years previously and underwent LT because of tumor recurrence. Thirty-two patients were treated while on the waiting list by either percutaneous ethanol injection (5 patients) radiofrequency ablation (3 patients), or transarterial chemoembolization (24 patients).
Fine-needle aspiration biopsy was performed in 18 patients, resulting in the diagnosis of HCC in 12 patients. In the remaining 6 patients, LT was indicated despite a cytological specimen negative for malignancy because the diagnosis of HCC was highly probable on the basis of imaging techniques. In 5 of these 6 patients, pathological examination of the liver confirmed the diagnosis of HCC (in 1 patient, complete necrosis of the nodule was observed after transarterial chemoembolization). In another 29 patients, preoperative diagnoses of HCC were based on radiological examination. Pathological examination of the liver confirmed the diagnosis in 24 patients (in 5 patients with single nodules, preoperative treatment achieved total necrosis of the tumor).
The number, site, and size of all tumor nodules found in the explanted liver, histological differentiation grade according to criteria of Edmonson and Steiner, 12 and the presence of vascular invasion were obtained from pathological records. The presence of tumor capsule was not considered for analysis because preoperative treatment achieved complete necrosis in 11 of the patients with solitary nodules.
Immunosuppressive therapy consisted of cyclosporine or tacrolimus, azathioprine, and prednisone. Patients who underwent LT for chronic hepatitis B virus infection were administered prophylaxis with intravenous hepatitis B immune globulin. Patients with a postoperative diagnosis of vascular invasion and/or more than 10 tumor nodules were considered for adjuvant chemotherapy with doxorubicin (60 mg/m 2 intravenously, every 4 weeks for 4 cycles) starting within the first postoperative month after serum bilirubin levels were less than 3 mg/dL. The 3 patients with more than 10 tumor nodules and 7 of 9 patients with vascular invasion underwent such therapy. In 2 patients, chemotherapy was not started because of postoperative complications.
Screening for tumor recurrence was by measurements of alphafetoprotein, abdominal ultrasound, and chest radiograph every 6 months and when clinically indicated. Diagnosis of HCC recurrence was based on pathological examination in all cases.
Patients were followed up until February 20, 2000, a follow-up for survivors of at least 8 months.
Statistical Analysis
Epidemiological and laboratory values are expressed as mean and interquartile range. Length of follow-up is shown as median and range.
Patients with HCC diagnosed before LT and patients without HCC were compared for age, sex, Child-Pugh status, 13 cause of liver cirrhosis (viral v nonviral), and time on the waiting list before LT by using 2-tailed Student's t-test for continuous variables and Chi-squared test and Fisher's exact test, as appropriate, for categorical variables. Kaplan-Meier method was used to obtain actuarial survival rates, and both curves were compared using the log-rank test.
The influence on recurrence-free survival of the following variables was assessed: age (Ͼ60 v Ͻ60 years), sex, viral liver disease, biopsy of the tumor before LT, Child's class (A versus B or C), Okuda's stage 14 
Results
Basal characteristics of patients with and without HCC are listed in Table 1 . Patients with HCC were older and had better liver function than patients without HCC, and their liver disease was more frequently of viral origin.
Ten patients in the HCC group and 15 patients in the non-HCC group died after a median follow-up of 33 months (range, 2 to 116 months) and 51 months (range, 0 to 119 months), respectively. Cause and time of death of patients in both groups are listed in Table 2 . Main causes of death in both groups were infectious diseases. Two patients died of tumor recurrence 7 and 9 months after LT. Actuarial survival (Fig. 1) was not significantly different between the groups.
Clinical staging and main radiological and pathological tumor characteristics are listed in Table 3 .
Accuracy of Liver Imaging
CT staging was compared with pathological findings. Radiological assessment had a trend to underestimate the number of tumor nodules; 14 of 31 patients (45%) with solitary HCC assessed by imaging techniques were found to bear additional nodules. Radiological TNM staging underestimated pTNM in 23 cases (49%) and overestimated it in 2 cases (4%). The upgrade of pTNM staging was caused by the detection of vascular invasion in the liver explant in 4 cases.
Recurrence
Tumor recurred in 6 patients at 5, 9, 16, 17, 32, and 33 months after LT. Sites of recurrence were lung (5 cases), liver (2 cases), bone (1 case), chest wall (1 case), and lymph nodes (1 case). Patients' main baseline characteristics are listed in Table 4 . Two patients died of tumor recurrence 7 and 9 months after LT, another patient with tumor recurrence died of an unrelated cause (biliary complications secondary to hepatic artery thrombosis) 18 months after LT, and 3 patients are currently alive 42, 50, and 63 months after LT. Figure  2 shows the actuarial recurrence-free survival curve. Table 5 lists 1-, 2-, and 3-year actuarial disease-free survival rates in the HCC group for those variables reaching significance in univariate analysis. Patients with viral liver disease, bilobar tumor, pTNM stage IV, and microscopic vascular invasion had poorer diseasefree survival than patients with nonviral liver disease; unilobar HCC; pTNM stages I, II or III; and without microscopic vascular invasion. In multivariate analysis, the only factor independently associated with mortality or recurrence was pTNM stage IV compared with stages I, II, and III (adjusted relative risk, 3.91; 95% confidence interval, 1.26 to 12.13; P ϭ .02).
Analysis of Factors Predictive of Disease-Free Survival

Discussion
Results of the present study confirm that selected patients with liver cirrhosis and HCC may undergo LT with excellent results. In our center, LT was considered in patients with solitary HCC with a maximum diameter of 60 mm and those with 2 or 3 nodules up to 50 mm. Using these selection criteria, survival rates of patients with and without HCC were similar. One-, 3-, and 5-year survival estimates for patients with HCC were 87%, 79%, and 79%, and 1-, 2-, and 3-year actuarial recurrence-free survival rates rates were 87%, 82%, and 70%, respectively. These results are similar to those of previous series of liver transplant recipients with HCC at an early stage. 2, [4] [5] [6] In previous reports of selected series of LT recipients with HCC, Mazzaferro et al 4 found that survival was higher in patients with correct preoperative staging within their inclusion criteria than in patients with more advanced disease, and Figueras et al 6 found that patients with tumor nodules greater than 5 cm and macroscopic vascular invasion had a greater mortality rate. Conversely, Llovet et al 5 did not find a correlation between tumor characteristics and patient outcome, but in this series, 12% of the patients had incidental HCC. In our study, patients with cirrhosis of viral origin, microscopic vascular invasion, bilobar disease, and pTNM stage IV did worse than patients with non- viral cirrhosis, no vascular invasion, unilobar disease, or pTNM stages I to III. The only factor independently predictive of recurrence or mortality was pTNM stage IV, suggesting that LT should be questioned in patients with HCC and pTNM stage IV, as suggested in series of unselected liver transplant recipients with HCC. Unfortunately, only 6 of 14 patients (43%) with pTNM stage IV were correctly staged on a CT basis, and when the worst stage of a combination of imaging techniques was used, only 8 of 14 patients (57%) were correctly identified. Conversely, no patient was misdiagnosed as TNM stage IV on a CT basis. The use of iodized-oil CT scan has been reported to be very useful in the preoperative staging of HCC, with an agreement of 96% between radiological and pathological staging, 18 but in the present series, such agreement was not found. The possible role of adjuvant chemotherapy in this group of patients with a high risk for tumor recurrence remains unclear. Encouraging results have been obtained with the use of doxorubicin 19 and the combination of doxorubicin and cisplatin. 20 In our series, postoperative doxorubicin was administered to patients believed to have a high risk for tumor recurrence, but half these patients had tumor recurrence. All but one of the patients with HCC with recurrence had been administered adjuvant chemotherapy. However, whether adjuvant chemotherapy may have influenced the time to recurrence in these patients could not be determined.
We could not ascertain whether pre-LT treatment might reduce the risk for post-LT HCC recurrence. Pre-LT treatment achieved complete tumor necrosis in 11 cases. None of them had post-LT recurrence. Conversely, only 1 of 15 patients with a single nonnecrotic nodule had recurrence.
In summary, patients with small HCCs who undergo LT have a survival similar to that of patients with liver cirrhosis without HCC and an acceptable recurrence-free survival rate. pTNM stage IV helps distinguish a subset of patients with a poor oucome, but imaging techniques are not accurate enough to predict pTNM stage because they miss a significant proportion of patients with pTNM stage IV. Radiological TNM stage IV might be considered a contraindication for LT. 
